Skip to content
value.today

Medgenics, Inc.

Total raised
$42 M
3 rounds on record
Latest round
$28 M
Oct 2017
First round on record
Sep 2010
Today
Private
No later event on record

Funding rounds

3 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Medgenics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Oct 2017$28 MNo. 3$10 to $50 million

Medgenics, Inc.: Raise no. 3, Oct 2017

Investors in this round

12 investors had bought by the notice of Oct 19, 2017: 12 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$28 M of $28 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Brian F. Piper · Executive Officer
  • Garry A. Neil · Executive Officer
  • Michael F. Cola · Executive Officer, Director
  • Alastair Andrew Clemow · Director
  • Barbara Andrew Duncan · Director
  • Eugene Andrew Bauer · Director
  • Joseph J. Grano Jr. · Director
  • Sol J. Barer · Director
  • Wilbur H. Gantz · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Brian D. Piper, Chief Financial Officer. Source: SEC Form D, newest notice filed Oct 19, 2017. Read the notice at the SEC.

equity, optionsSEC
Oct 2015$3 MIssued in a merger or acquisition$2 to $10 million

Medgenics, Inc.: Private sale, Oct 2015

Investors in this round

1 investor had bought by the notice of Oct 15, 2015: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Garry A. Neil · Executive Officer
  • John H. Leaman · Executive Officer
  • Michael F. Cola · Executive Officer, Director
  • Scott H. Applebaum · Executive Officer
  • Alastair Andrew Clemow · Director
  • Barbara Andrew Duncan · Director
  • Eugene Andrew Bauer · Director
  • Isaac Andrew Blech · Director
  • Joseph J. Grano Jr. · Director
  • Sol J. Barer · Director
  • Wilbur H. Gantz III · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by John H. Leaman, Chief Financial Officer. Source: SEC Form D, newest notice filed Oct 15, 2015. Read the notice at the SEC.

equitySEC
Jun 2012$10 MNo. 2$2 to $10 million

Medgenics, Inc.: Raise no. 2, Jun 2012

Investors in this round

88 investors had bought by the notice of Jul 2, 2012: 88 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$10 M of $10 M offered
Smallest investment taken
$15,000
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$952,919
Finders' fees
none
Paid to its own people
$555,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions and payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andrew Leonard Pearlman, PhD · Executive Officer, Director
  • Clarence L. Dellio · Executive Officer
  • Phyllis Devon Bellin · Executive Officer
  • Stephen Devon Bellomo · Executive Officer
  • Alastair Devon Clemow, PhD · Director
  • Eugene Andrew Bauer, MD · Director
  • Gary Allan Brukardt · Director
  • Isaac Devon Blech · Director
  • Joel Stephen Kanter · Director
  • Stephen Devon McMurray, MD · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Maxim Group LLC (CRD 281147) · New York, New YorkSold in all US states

Remarks in the notice

  • On the use of proceeds: “proceeds to be used for general corporate purposes including payment of salaries”

Signed by Andrew L. Pearlman, CEO and President. Source: SEC Form D, newest notice filed Jul 2, 2012. Read the notice at the SEC.

equity, optionsSEC
Sep 2010$4 MNo. 1$2 to $10 million

Medgenics, Inc.: Raise no. 1, Sep 2010

Investors in this round

17 investors had bought by the notice of Nov 4, 2010: 17 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $4 M offered
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$222,350
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions and payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andrew Leonard Pearlman · Executive Officer, Director
  • Baruch Devon Stern · Executive Officer
  • Phyllis Devon Bellin · Executive Officer
  • Stephen Devon Bellomo · Executive Officer
  • Alastair Devon Clemow · Director
  • Eugene Andrew Bauer · Director
  • Gary Allan Brukardt · Director
  • Joel Stephen Kanter · Director
  • Stephen Devon McMurray · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Maxim Group LLC (CRD 120708) · New York, New YorkSold in NY
  • Equity Source Partners, LLC (CRD 140227) · Huntington, New YorkSold in NJ, NY

Remarks in the notice

  • On fees: “Excludes warrants to purchase 1,612,500 shares of common stock issued as compensation.”

Signed by Andrew Pearlman, President. Source: SEC Form D, newest notice filed Nov 4, 2010. Read the notice at the SEC.

debt, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Medgenics, Inc. had no revenue when it filed its newest notice of a funding round (Oct 2017).

    SEC Form D (revenue range) · Oct 2017

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Oct 2017

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Medgenics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 88 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Medgenics, Inc.
NameRoleNamed in
Brian F. PiperExecutive officerOct 2017
Garry A. NeilExecutive officerOct 2017
Michael F. ColaExecutive officerOct 2017
John H. LeamanExecutive officerOct 2015
Scott H. ApplebaumExecutive officerOct 2015
Andrew Leonard Pearlman, PhDExecutive officerJul 2012
Clarence L. DellioExecutive officerJul 2012
Phyllis Devon BellinExecutive officerJul 2012
Stephen Devon BellomoExecutive officerJul 2012
Andrew Leonard PearlmanExecutive officerNov 2010
Baruch Devon SternExecutive officerNov 2010
Alastair Andrew ClemowDirectorOct 2017
Barbara Andrew DuncanDirectorOct 2017
Eugene Andrew BauerDirectorOct 2017
Joseph J. Grano Jr.DirectorOct 2017
Michael F. ColaDirectorOct 2017
Sol J. BarerDirectorOct 2017
Wilbur H. GantzDirectorOct 2017
Isaac Andrew BlechDirectorOct 2015
Wilbur H. Gantz IIIDirectorOct 2015
Alastair Devon Clemow, PhDDirectorJul 2012
Andrew Leonard Pearlman, PhDDirectorJul 2012
Eugene Andrew Bauer, MDDirectorJul 2012
Gary Allan BrukardtDirectorJul 2012
Isaac Devon BlechDirectorJul 2012
Joel Stephen KanterDirectorJul 2012
Stephen Devon McMurray, MDDirectorJul 2012
Alastair Devon ClemowDirectorNov 2010
Andrew Leonard PearlmanDirectorNov 2010
Stephen Devon McMurrayDirectorNov 2010